Breakthrough ME/CFS Blood Test Could End Decades of Misdiagnosis

By Beth Emerson

People with chronic fatigue syndrome, also referred to as ME/CFS, for decades have been told it’s all in their head. Without a viable means to test for it, it’s been dismissed either as a psychological issue and even, conveniently, not an illness at all. Now, a ground-breaking UK study claims to have developed the first blood test which is capable of identifying the condition with striking accuracy, using the 3D structure of DNA. The test, developed through a collaboration between scientists at the University of Anglia and Oxford Biodynamics, offers the hope that the diagnosis could soon be as simple as a routine blood test [1].

‘It’s all in your head’…until it isn’t

ME/CFS is estimated to affect around 400,000 people in the UK [2], yet diagnosis can take years. Its hallmark symptoms: crushing fatigue, brain fog, and a post-exercise “crash” after even lowlevel activity, yet these don’t appear on routine medical screens. This invisibility has long contributed to stigma. Lacking a quantifiable marker, patients have been told they are mentally ill, or that their sickness is imaginary.

Lead researcher Prof Dmitry Pshezhetskiy, from UEA’s Norwich Medical School, said “For the first time, we have a simple blood test that can reliably identify ME/CFS – potentially transforming how we diagnose and manage this complex disease.” [3]

In other words, this test may put to rest forever the mind–body divide that has plagued patients for centuries. For so many, having concrete proof on paper would mark the end of medical gaslighting and the beginning of being believed.

Reading the folds of DNA

At the heart of the new test lies epigenetics, the science of how genes are switched on or off without changing the genetic code itself. DNA is like a huge library, and epigenetics is the system of bookmarks that decides which books are opened and read. Researchers aren’t changing the library itself (the genes) but studying how the shelves are organised, how certain sections are folded or closed off. The new test detects these unique folding ‘signatures’, showing how the immune system’s instruction manuals are being accessed diƯerently in people with the condition.

The scientists used EpiSwitch 3D Genomic Profiling, a technology that maps the physical looping and folding of DNA in cells. These intricate folds, known as chromatin loops, control how genes pass on information. The team found distinct patterns of folding in people with ME/CFS, generating a sort of biological fingerprint for the condition [1].

Applying machine learning to these patterns, the test achieved 92% sensitivity (correctly selecting individuals with ME/CFS) and 98% specificity (correctly ruling out healthy controls) [1]. Imagine a dog taught to find one unusual smell, it never misses what it’s looking for and rarely barks at the wrong thing.

When algorithms meet the immune system

What makes this research exciting is the fusion of biology and technology. The research blends 3D genome mapping, artificial intelligence, and data modelling, approaches more often associated with astrophysics than diagnostics.

By training algorithms to detect slight variations in folds that the human eye cannot see, researchers can now extract molecular data from a single blood sample. It’s a living testament to how computing is transforming medicine, not by replacing doctors, but by giving them sharper tools to see the unseeable.

As Oxford BioDynamics’ press release states, ‘understanding the biological pathways involved in ME/CFS opens the door to developing targeted treatments’ [4].

The intersection of tech and biology may also lead to a test for other related disorders, such as long COVID [5].

Proof at last: What it means for patients

For ME/CFS patients, a diagnosis can arrive after years and only after countless appointments, dismissal, and emotional strain. A reliable blood test oƯers something simple but potent: evidence. Evidence the disease is biological, not imagined. The test could help doctors intervene earlier, improve care, and allow researchers to group patients more precisely, critical steps toward effective treatments.

Patient groups have welcomed this news, as they believe a definitive test could force doctors to take ME/CFS more seriously [6].

Still, scientists urge caution

The study involved 47 people with severe ME/CFS and 61 healthy controls, this is a small sample [1]. It remains unclear whether the same DNA-folding signature appears in people with milder symptoms or overlaps with conditions like long COVID or fibromyalgia [7].

Replication in more extensive, more diverse cohorts is essential before the test can be used in a clinical setting. There are also some practical concerns: expense, availability, and how to incorporate such advanced genomics into day-to-day medicine [1]. Still, the work is a milestone. For the first time, ME/CFS has a measurable biological marker; evidence that what was long dismissed as psychosomatic may indeed be written within our cells.

A Turning Point in Sight

Whether or not this becomes standard practice, it changes the nature of how science deals with illnesses that cannot be seen through a microscope. Epigenetics technologies like EpiSwitch® illustrate to us that disease is not always about malfunctioning genes, it can be about how the genes fold and are controlled [1].

As research continues, one thing is certain: the history of ME/CFS is being rewritten, not as a mystery of the mind, but as an illness inscribed into our genes.

References

[1] Hunter, E. et al. “Development and Validation of Blood-Based Diagnostic Biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Using EpiSwitch 3-Dimensional Genomic Profiling.” Journal of Translational Medicine, October 8, 2025. https://translationalmedicine.biomedcentral.com/articles/10.1186/s12967-025-07203-w

[2] JeƯeries, Emma. “Prevalence: Latest Research Suggests a 62% Increase on Historic Estimates for ME/CFS in the UK – the ME Association.” The ME Association. July 4, 2025. https://meassociation.org.uk/2025/07/prevalence-latest-research-suggests-a-62-increase-onhistoric-estimates-for-me-cfs-in-the-uk/.

[3] “Revolutionary Blood Test for ME / Chronic Fatigue Unveiled.” 2025. EurekAlert! October 7, 2025. https://www.eurekalert.org/news-releases/1101039.

[4] Investegate. 2025. “OBD and UEA Develop Test for Chronic Fatigue | Company Announcement |” Investegate. October 8, 2025. https://www.investegate.co.uk/announcement/rns/oxford-biodynamics–obd/obd-and-uea-develop-test-for-chronic-fatigue/9156866

[5] Pickover, Ella. 2025. “‘Breakthrough’ as Scientists Develop First-Ever Test for Debilitating
Condition.” The Independent. October 8, 2025. https://www.independent.co.uk/news/health/me-cfs-symptoms-blood-test-chronic-fatiguesyndrome-b2841122.html.

[6] Vince, Josh. 2025. “Researchers Say They Have Developed the World’s First Accurate Blood Test to Diagnose ME/CFS.” Action for ME. October 8, 2025. https://www.actionforme.org.uk/research-blood-test-mecfs/.

[7] Cassella, Carly. 2025. “New Chronic Fatigue Syndrome ‘Blood Test’ Raises Hope and
Skepticism.” ScienceAlert. October 13, 2025. https://www.sciencealert.com/new-chronicfatigue-syndrome-blood-test-raises-hope-and-skepticism?.